6th Genome Editing Therapeutics Summit 2025 To Convene In Boston

Boston, MA – September 16, 2025 – The 6th Genome Editing Therapeutics Summit is scheduled to take place from September 30 to October 1, 2025, at the Wyndham Boston Beacon Hill. Organized by Hanson Wade, the summit will bring together over 100 leaders from pharmaceutical companies, biotechnology firms, and academic institutions to discuss the latest breakthroughs and future directions in genome editing for therapeutic applications.

The summit will provide an in-depth exploration of key topics such as in vivo and ex vivo gene editing, precision targeting, novel delivery technologies, and regulatory strategies for bringing genome-editing therapies to the clinic. Participants will have the opportunity to engage in interactive discussions on cutting-edge research, clinical developments, and real-world case studies that highlight both successes and challenges in the field.

Over the course of two days, attendees can expect a dynamic program featuring keynote presentations, panel discussions, and practical workshops. Day one will focus on recent innovations in gene-editing platforms and the development of next-generation therapeutic strategies. Day two will cover clinical translation, regulatory pathways, and the challenges of scaling genome-editing therapies for widespread patient access. The summit will also provide dedicated networking sessions to foster collaboration among scientists, industry leaders, and investors.

The event will feature a distinguished lineup of speakers from leading organizations. Confirmed speakers include Alexandria Petrusich, Vice President of Clinical Science at Prime Medicine; Chris Brown, Vice President of Discovery at Metagenomi; Priya S. Chockalingam, Vice President and Head of Clinical Bioanalytics & Translational Sciences at Beam Therapeutics; and other experts who are shaping the future of genome-editing therapeutics. Their presentations will offer attendees unique insights into the latest scientific developments, technological advancements, and strategies for overcoming current industry challenges.

Registration for the summit is now open, with early bird pricing available for a limited period. Group discounts are also offered to encourage participation from multiple members of the same organization. The summit promises to be a valuable platform for anyone involved in gene therapy research, development, and commercialization.

Hanson Wade, the organizer of the summit, is a renowned provider of scientific conferences and is committed to fostering collaboration, innovation, and knowledge exchange in the life sciences. Their events are designed to connect leading minds across academia, industry, and investment to accelerate the development of transformative therapies.

Pharma Now is the official media partner for the 6th Genome Editing Therapeutics Summit 2025. As the event’s media partner, Pharma Now will provide extensive coverage, share exclusive insights, and highlight the latest advancements and innovations presented at the summit. Through this partnership, Pharma Now aims to ensure that the global pharmaceutical and biotechnology community remains informed and engaged with the latest developments in genome-editing therapeutics.